Skip to content
Clinical Trials – home
SloveniaBack to Slovenia

Clinical trials in Sempeter Pri Gorici – page 24

392 clinical trials in Sempeter Pri Gorici, Slovenia. Every trial is listed in the EU Clinical Trials Register and updated daily.

SloveniaOur site in SloveniaKlinicnaPreskusanja.si(opens in a new tab)
Sempeter Pri Gorici at a glance
392
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

392 trials in Sempeter Pri Gorici

Open in trial search

Mantle cell lymphoma

Not recruiting

Study on Rituximab, Bendamustine, Cytarabine, and Venetoclax for High-Risk Elderly Patients with Mantle Cell Lymphoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cytarabine
  • Sponsor:Fondazione Italiana Linfomi Ets

Plasma cell myeloma

Not recruiting

Study Comparing Isatuximab with Carfilzomib, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple Myeloma Patients Eligible for Stem Cell Transplant

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Carfilzomib
  • Sponsor:Emn Trial Office S.r.l. Impresa Sociale

Study Comparing Trastuzumab Deruxtecan with Chemotherapy for Patients with HER2-Low, Hormone Receptor Positive Breast Cancer After Endocrine Therapy Progression

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:AstraZeneca AB

Study on the Effectiveness of OPT-302 and Ranibizumab for Patients with Wet Age-related Macular Degeneration

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:OPT-302
  • Sponsor:Opthea Limited

Study Comparing Panitumumab and Regorafenib Sequence for Patients with Metastatic Colorectal Cancer Resistant to Previous Treatments

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Panitumumab
  • Sponsor:Gruppo Oncologico Del Nord Ovest

Study on the Safety and Effectiveness of Trifluridine/Tipiracil, Capecitabine, and Bevacizumab for Patients with Metastatic Colorectal Cancer Unfit for Intensive Chemotherapy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Gruppo Oncologico Del Nord Ovest

Malignant melanoma

Not recruiting

Study Comparing Naporafenib and Trametinib Combination to Other Therapies for Patients with Previously Treated Unresectable or Metastatic NRAS Mutant Melanoma

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Dacarbazine
  • Sponsor:Erasca Inc.

Study of emapalumab in children and adults with Macrophage Activation Syndrome (MAS) occurring in Still's Disease or Systemic Lupus Erythematosus

InvestigationalNo placebo
Countries:CzechiaCzechia
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Emapalumab
  • Sponsor:Swedish Orphan Biovitrum AG

Study on Elamipretide for Patients with Dry Age-Related Macular Degeneration (Dry AMD)

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Elamipretide Trihydrochloride
  • Sponsor:Stealth Biotherapeutics Inc.

Malignant melanoma

Not recruiting

Study on Fianlimab and Cemiplimab for Adults with Resectable Stage III and IV Melanoma

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Cemiplimab
  • Sponsor:Regeneron Pharmaceuticals Inc.

Study on Ponatinib and Blinatumomab for Adults with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Blinatumomab
  • Sponsor:Fondazione G.I.M.Em.A Franco Mandelli Ets

Study on the Effect of Cemiplimab in Patients with Oligometastatic Non-Small Cell Lung Cancer After Radical Treatment

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Cemiplimab
  • Sponsor:Europese Organisatie Voor Onderzoek En Behandeling Van Kanker Organisation Europeenne Pour La Recherche Et Le Traitement Du Cancer European Organi

Other cities in Slovenia

The busiest research cities in the country

All 18 cities in Slovenia

Clinical research in Sempeter Pri Gorici

What the registry says about research in the country

01 Diseases of the Digestive System

Clinical trial research in Sempeter Pri Gorici includes studies focused on digestive system diseases, with attention on improving care for people living with ulcerative colitis. The trials are looking at new treatment options that may help better control inflammation and support symptom management.

  • Key field: gastroenterology
  • Main disease studied: ulcerative colitis
  • Research goal: comparing the effectiveness and safety of newer therapies

These studies are designed to strengthen treatment choices for adults with moderate to severe disease.

02 Nutritional and Metabolic Diseases

Another active area covers nutritional and metabolic diseases, especially type 2 diabetes. Research here is centered on finding better ways to lower blood sugar and improve overall metabolic control in people whose diabetes is not yet adequately managed.

  • Key field: endocrinology
  • Main disease studied: type 2 diabetes
  • Research goal: testing a new therapy against an established treatment
  • Clinical focus: improving glucose control and supporting weight management

The local trial activity reflects a clear interest in refining long-term treatment approaches for diabetes.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.